All In Biotech

Drug Trial Radar · NCT04725474

First-in-Human Study of the GDF-15 Neutralizing Antibody Visugromab (CTL-002) in Patients With Advanced Cancer (GDFATHER)

A Phase 1/2, FIH, Two-part, Open-label Clinical Trial of Intravenous (IV) Administration of CTL-002 Given as Monotherapy and/or in Combination With an Anti-PD-1 Checkpoint Inhibitor in Subjects With Advanced-stage, Relapsed/Refractory Solid Tumors (The "GDFATHER"-Trial: GDF-15 Antibody-mediaTed Human Effector Cell Relocation).

Last checked: Nov 19, 2026Latest source record: Aug 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

199

Actual

Start

Dec 9, 2020

Primary completion

Apr 30, 2028

Study completion Apr 30, 2030

Sponsor

Lead sponsor
CatalYm GmbHIndustry
Sponsor type
Industry
First posted
Jan 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The Phase 1 part (Part A) is a dose escalation study of IV visugromab (CTL-002, a monoclonal antibody neutralizing GDF-15) as monotherapy and in combination with an approved checkpoint inhibitor (CPI) in patients with advanced solid tumors. Enrolment into the Ph 1 part is completed. The Phase 2 parts (Part B) are cohort expansions with visugromab (CTL-002) in combination with a defined CPI at a fixed dose into seven different solid tumor indications. Enrolment into the Ph 2 part is completed.

Conditions

  • Solid Tumor, Adult

Interventions

  • visugromab (CTL-002)Biological

    monoclonal antibody

  • nivolumabBiological

    monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse Events (Parts A & B)Time frame: min. 2 months
  2. Determination of DLT and MTD (Part A)Time frame: 28 days
  3. Evaluation of clinical efficacy according RECIST V1.1 (Part B)Time frame: min. 6 weeks

Locations

13 sites in 3 countries. Site status is shown where the registry gives one.

  • Universitätsklinikum Essen, Westdeutsches Tumorzentrum, Innere Klinik und Poliklinik

    Essen, Germany

  • Universitätsklinikum Frankfurt, Medizinische Klinik I

    Frankfurt am Main, Germany

  • Universitätsklinikum Würzburg, Comprehensive Cancer Center

    Würzburg, Germany

  • Next Oncology, Phase I Unit. IOB - Hospital Quironsalud

    Barcelona, Spain

  • Hospital Universitari Vall d'Hebron, Institute of Oncology

    Barcelona, Spain

  • ICMDiM, Hospital Clinic

    Barcelona, Spain

  • ICO Hospitalet, Hospital Duran i Reynals

    Barcelona, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • START Madrid, Hospital Universitario HM Sanchinarro

    Madrid, Spain

  • Clinica Universidad de Navarra, Unidad Central de Ensayos Clinicos

    Pamplona, Spain

  • University Hospital Basel, Department for Medical Oncology

    Basel, Switzerland

  • Kantonsspital St. Gallen, Clinic for Medical Oncology & Hematology

    Sankt Gallen, Switzerland

  • University Hospital Zurich, Department of Dermatology

    Zurich, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.